Rx0000090 |
UCB, Inc |
03/31/2020 |
50474087015 |
BRIVIACT CV 10 MG/ML, 300ML ORAL SOLUTION |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474077009 |
BRIVIACT CV 100 MG, 100 UNIT DOSE TABLETS |
01/01/2020 |
57.25 |
1965.59 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474077066 |
BRIVIACT CV 100 MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474037066 |
BRIVIACT CV 10MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474047009 |
BRIVIACT CV 25MG, 100 UNIT DOSE TABLETS |
01/01/2020 |
57.25 |
1965.59 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474047066 |
BRIVIACT CV 25MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474057066 |
BRIVIACT CV 50MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474057009 |
BRIVIACT CV 5OMG, 100 UNIT DOSE TABLETS |
01/01/2020 |
57.25 |
1965.59 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474067066 |
BRIVIACT CV 75MG, 60 TABLETS |
01/01/2020 |
34.35 |
1179.35 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474097075 |
BRIVIACT INJECTION FOR INTRAVENOUS USE, CV 50 MG/5ML, 10 VIALS |
01/01/2020 |
14.71 |
505.43 |
02/21/2021 |
Single Source Drug |
190230000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474070062 |
CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS |
01/01/2020 |
302.92 |
4630.35 |
02/13/2024 |
Single Source Drug |
1217472000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474071079 |
CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES |
01/01/2020 |
302.92 |
4630.35 |
02/13/2024 |
Single Source Drug |
1217472000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474071081 |
CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES |
01/01/2020 |
908.75 |
13891.04 |
02/13/2024 |
Single Source Drug |
1217472000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080103 |
NEUPRO 1 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080203 |
NEUPRO 2 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080303 |
NEUPRO 3 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080403 |
NEUPRO 4 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080503 |
NEUPRO 6 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
50474080603 |
NEUPRO 8 MG, 30 PATCHES |
01/01/2020 |
32.95 |
705.43 |
12/22/2030 |
Single Source Drug |
108543000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247835 |
VIMPAT CV 100MG, 60 TABLETS |
01/01/2020 |
25.92 |
890.25 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247860 |
VIMPAT CV 100MG, 60 UNIT DOSE TABLETS |
01/01/2020 |
28.52 |
979.35 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131541071 |
VIMPAT CV 10MG/ML ORAL SOLUTION, 200 ML |
01/01/2020 |
10.72 |
368.30 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131541070 |
VIMPAT CV 10MG/ML ORAL SOLUTION, 465 ML |
01/01/2020 |
21.45 |
736.59 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247935 |
VIMPAT CV 150MG, 60 TABLETS |
01/01/2020 |
27.46 |
942.85 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247960 |
VIMPAT CV 150MG, 60 UNIT DOSE TABLETS |
01/01/2020 |
30.22 |
1037.19 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131248035 |
VIMPAT CV 200MG, 60 TABLETS |
01/01/2020 |
27.46 |
943.11 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131248060 |
VIMPAT CV 200MG, 60 UNIT DOSE TABLETS |
01/01/2020 |
30.22 |
1037.52 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247735 |
VIMPAT CV 50MG, 60 TABLETS |
01/01/2020 |
16.58 |
569.43 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131247760 |
VIMPAT CV 50MG, 60 UNIT DOSE TABLETS |
01/01/2020 |
18.23 |
626.43 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000090 |
UCB, Inc |
03/31/2020 |
00131181067 |
VIMPAT INJECTION FOR INTRAVENOUS USE, CV 200MG/20ML, 10 VIALS |
01/01/2020 |
22.68 |
778.94 |
03/17/2022 |
Single Source Drug |
1120119000 |
None |
None |
1 |
The price increases are not necessitated by a change or improvement in the drugs. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
Rx0000036 |
United Therapeutics |
09/30/2020 |
66302020603 |
"Tyvaso 1.74 mg Inhalation 2.9 mL/ampule *4" |
07/01/2020 |
111.42 |
2587.32 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency
This information is confidential and proprietary, and not publicly available or within the public domain. |
Rx0000036 |
United Therapeutics |
09/30/2020 |
66302020604 |
"Tyvaso 1.74 mg Inhalation 2.9 mL/ampule*4" |
07/01/2020 |
201.54 |
4680.17 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency
This information is confidential and proprietary, and not publicly available or within the public domain. |
Rx0000036 |
United Therapeutics |
09/30/2020 |
66302020602 |
"Tyvaso Refill kit 1.74 mg Inhalation 2.9 mL/ampule * 28" |
07/01/2020 |
779.91 |
18111.22 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency
This information is confidential and proprietary, and not publicly available or within the public domain. |
Rx0000036 |
United Therapeutics |
09/30/2020 |
66302020601 |
"Tyvaso Starter kit 1.74 mg Inhalation 2.9 mL/ampule * 28" |
07/01/2020 |
870.03 |
20204.08 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
While we believe reporting is not required under the law, we are nonetheless providing a report out of our desire to support greater pricing transparency
This information is confidential and proprietary, and not publicly available or within the public domain. |
Rx0000036 |
United Therapeutics |
09/30/2020 |
66302001401 |
"Unituxin 17.5mg/5 ML Injection/vial 5ml Vial" |
08/15/2020 |
401.77 |
11880.77 |
03/01/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain. |
Rx0000036 |
United Therapeutics |
03/31/2020 |
66302001401 |
Unituxin Dinutuximab; 17.5mg/5mL; Injection/vial; 5mL vial |
01/01/2020 |
639.50 |
11479.00 |
03/01/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit sales data- This information is confidential and proprietary, and not publicly available or within the public domain.
Cost increase factors- This information was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain.
Change/Improvement description- This information was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain.
Acquisition fields have not been completed because the product was not acquired from another manufacturer within the last 5 years |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107430 |
Qudexy XR 100mg Cpsl Btl 30 |
01/31/2020 |
37.06 |
654.75 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107530 |
Qudexy XR 150mg Cpsl Btl 30 |
01/31/2020 |
45.59 |
805.38 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107330 |
Qudexy XR 200mg Cpsl Btl 30 |
01/31/2020 |
50.70 |
895.67 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107130 |
Qudexy XR 25mg Cpsl Btl 30 |
01/31/2020 |
14.36 |
253.70 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00245107230 |
Qudexy XR 50mg Cpsl Btl 30 |
01/31/2020 |
18.71 |
330.47 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107430 |
Topiramate ER 100mg Cpsl Btl 30 |
01/31/2020 |
30.22 |
533.91 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107530 |
Topiramate ER 150mg Cpsl Btl 30 |
01/31/2020 |
37.17 |
656.72 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107330 |
Topiramate ER 200mg Cpsl Btl 30 |
01/31/2020 |
41.34 |
730.38 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107130 |
Topiramate ER 25mg Cpsl Btl 30 |
01/31/2020 |
11.71 |
206.89 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |
Rx0000161 |
Upsher-Smith Laboratories, LLC |
03/31/2020 |
00832107230 |
Topiramate ER 50mg Cpsl Btl 30 |
01/31/2020 |
15.25 |
269.48 |
03/19/2033 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product not acquired so data not provided in the acquisition-related fields
Drug is a single source drug as it is the authorized generic to Qudexy XR |